News

In a small proof-of-concept clinical trial, Biovie’s experimental oral therapy bezisterim was associated with significantly greater improvements in motor and nonmotor symptom scores than a placebo among people with early-stage Parkinson’s disease who had higher levels of a potential inflammation marker. The findings come from an exploratory subgroup analysis.

Women with Parkinson’s disease experience more severe motor complications and depression, while men are more likely to have cognitive difficulties, reduced sense of smell, and sleep disturbances, according to a large study in Germany. The findings, drawn from almost 11,000 people with Parkinson’s, suggest that the disease affects men…

Researchers at Mayo Clinic are testing whether low-dose radiation therapy can slow the progression of Parkinson’s disease by reducing inflammation in affected areas of the brain. According to Mayo Clinic, this is the first clinical trial (NCT07218952) to investigate low-dose radiation as an anti-inflammatory treatment approach in early-stage Parkinson’s.

XS411, Xellsmart’s experimental stem cell therapy, was generally well tolerated and associated with improved motor function in people with Parkinson’s disease, according to new Phase 1 clinical trial data. The trial (NCT07080775) enrolled nine people with moderate to advanced Parkinson’s. It also showed that the treatment improved…

People with Parkinson’s disease who carry GBA1 variants may experience faster cognitive decline when deep brain stimulation (DBS) is performed later rather than earlier in the disease course, a new study found. “These results should inform shared decision making between clinicians and patients and provide a rationale for prospective…

Cognitive issues affect about one in three people with Parkinson’s disease, a meta-analysis found, highlighting the importance of early screening and long-term research into the causes and early indicators of cognitive decline in patients. The researchers cautioned that the studies they looked at varied widely in diagnostic criteria and…

Remote-monitored home exercise may help people with Parkinson’s disease, but current evidence does not show that it is more effective than standard home exercise or therapist-led rehabilitation, according to a meta-analysis of more than a dozen randomized controlled trials. “It neither establishes an independent effect of remote monitoring nor…

Nicotinamide riboside (NR) — an oral supplement designed to increase nicotinamide adenine dinucleotide (NAD), a molecule needed for cells to produce energy and function properly — did not improve symptoms in people with Parkinson’s disease compared with a placebo in a Phase 3 clinical trial. “We had a strong…

The first patient has been dosed in Mission Therapeutics’ Phase 1b clinical trial of MTX325, an oral treatment for Parkinson’s disease. With several locations open in the U.K., France, Germany, and Australia, the Phase 1b clinical trial (NCT07630545) is still recruiting up to 36 adults aged 40-75…

In late 2025, the Parkinson’s Foundation and the Fixel Institute at the University of Florida brought together dozens of experts to ask a bold question: What will it take to bring about a world where no one has Parkinson’s disease? Now, that group — the Parkinson’s Disease Prevention…